comprehensive -WSS

comprehensive

author：hotspot 2025-08-19 20:47:55 - browse：95

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Skip the lead apron during X

entertainment

WSS

What we know about the American soldier detained in North Korea

AstraZeneca lung cancer study comes in below expectations

Lack of darker skin in textbooks, journals harms patients of color

The biotech scorecard for Q3: 15 stock

Skip the lead apron during X

UK homeowners get some respite as inflation falls by more than anticipated to a 15

hotspot

comprehensive

hotspot

Supreme Court strikes down use of affirmative action

Study: Hearing aids may slow cognitive decline in those at risk

Wildfire smoke exposes gaps in outdoor worker protections

Canadians with cystic fibrosis outlive Americans by a decade

Psychedelics group wrestles with new pharma identity

Twill hunts for pharma partner to market its depression app

Apple is now the first public company to be valued at $3 trillion

'Screen and refer' systems are hurting patients

Psychedelics group wrestles with new pharma identity

What we know about the American soldier detained in North Korea

focus

'Screen and refer' systems are hurting patients

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

A look at other Americans who have crossed into North Korea over the years

Security flaws in third

Lack of darker skin in textbooks, journals harms patients of color

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

hotspot

entertainment

focus

hotspot